Related Experiment Video

Updated: Jun 26, 2026

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

Activation of Akt as a mechanism for tumor immune evasion

Kyung Hee Noh1, Tae Heung Kang, Jin Hee Kim

  • 1Divison of Infection and Immunology, Graduate School of Medicine, Korea University, Seoul, South Korea.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|December 25, 2008
PubMed

Insights

The PI3K/Akt pathway activation helps tumors evade immune responses. Inhibiting Akt can improve cancer immunotherapy effectiveness against resistant tumors.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Tumor immune evasion hinders effective cancer immunotherapy.
  • Human papillomavirus type 16 (HPV-16) E7 oncoproteins are targets for cancer vaccines.
  • Understanding immune evasion mechanisms is crucial for developing new cancer treatments.

Purpose of the Study:

  • To investigate the mechanisms behind tumor immune evasion.
  • To identify novel therapeutic targets for overcoming immune resistance in cancer.

Main Methods:

  • Generation of an immune-resistant HPV-16 E7-expressing tumor cell line through in vivo immune selection.
  • Comparative analysis of parental and immune-resistant tumors.
  • Assessment of the role of Akt pathway activation in immune resistance.
  • Evaluation of Akt inhibitor efficacy in combination with immunotherapy.

Main Results:

  • Akt pathway activation was significantly higher in immune-resistant tumors.
  • Constitutively active Akt conferred resistance to CD8(+) T-cell mediated apoptosis.
  • Upregulation of antiapoptotic molecules correlated with Akt-mediated resistance.
  • Akt inhibition enhanced the therapeutic efficacy of E7-specific vaccines and T-cell adoptive transfer.

Conclusions:

  • PI3K/Akt pathway activation is a novel mechanism of tumor immune escape.
  • Targeting the Akt pathway offers a promising strategy for overcoming immune resistance in cancer immunotherapy.
  • Combination therapy involving Akt inhibitors and immunotherapy may improve treatment outcomes for resistant tumors.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...